Please assess the completion status of the following clinical trial:

Trial Title: Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years, male or female~* Diagnosis: multiple myeloma undergoing Autologous Stem Cell Transplantation (SCT)~* Planning to receive conditioning chemotherapy (Melphalan) for autologous stem cell transplantation and standard prophylactic antibiotics treatment.~* Can drink 200ml of mannitol and agrees to undergo stool, urine, and blood checks 3 times during the study.~* Agrees and able to take the investigational products or placebo starting from the day of completing conditioning therapy for a total of 4 weeks~Exclusion Criteria:~* Patients with history of inflammatory bowel disease will be excluded from the study.~* Patients with prior GI tract surgical (small or large bowel) resections~* The concurrent presence of systemic light chain amyloidosis~* Subject has known allergy or intolerance to beef or to any ingredient used in the product~* Women who are pregnant, breast-feeding and of child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: SBI + Placebo (Type: ACTIVE_COMPARATOR): Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
- Group B: Colesevelam + Placebo (Type: ACTIVE_COMPARATOR): Colesevelam 1.875 g + Placebo twice per day
- Group C: Colesevelam + SBI (Type: ACTIVE_COMPARATOR): Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
- Group D: Double Placebo (Type: PLACEBO_COMPARATOR): Double placebo twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).